When we evaluated the effect of SPHK inhibitors on the survival and activation of CD4+ and CD8+ T cells from CLL patients, we found that SKI-II and opaganib slightly reduce T cell activation, without affecting their survival. This evidence concerns the gene SPHK1 and B-cell chronic lymphocytic leukemia.